AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.
The AIDS Drug Assistance Programs (ADAPs) were founded in 1987 to pay for human immunodeficiency virus (HIV)-related medications in the United States and to help provide prescriptions for HIV-infected patients ineligible for Medicaid who have no private health insurance. As HIV care has shifted from the inpatient to the outpatient arena and as patients live longer because of more-effective antiretroviral therapy, medication costs have increased, and ADAPs have increasingly been operating under emergency measures, with coverage limitations and eligibility restrictions. Because these programs operate at the state level, inequalities in resource distribution to those in need are manifest and appear to contribute to differences in disease outcomes that are based solely on patients' place of residence. Cost-effectiveness analysis would offer a more informed basis for distribution of ADAP resources in an efficient and equitable manner, leading to a standardized national structure.
Walensky
Rochelle P
RP
Division of Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 , USA. rwalensky@partners.org
Paltiel
A David
AD
Freedberg
Kenneth A
KA
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000191:economics; D000553:Ambulatory Care; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005376:Financial Management; D017048:Health Care Costs; D006297:Health Services Accessibility; D006801:Humans; D019458:Insurance Coverage; D008483:Medical Assistance; D010593:Pharmaceutical Services / Q000191:economics; D013221:State Health Plans / Q000191:economics; D016896:Treatment Outcome; D014481:United States